BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35620896)

  • 1. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
    Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
    Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
    [No Abstract]   [Full Text] [Related]  

  • 2. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
    Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
    Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
    Pan M; Li Z; Jia M; Lu X
    Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
    Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
    Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
    Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
    Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
    Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to better stratify the risk of differentiated thyroid carcinomas: the key role of radioactive iodine therapy, age, and gender.
    Piccardo A; Siri G; Raffa S; Castellana M; Foppiani L; Bottoni G; Ugolini M; Cistaro A; Catrambone U; Altrinetti V; Massollo M; Arlandini A; Giovanella L; Cabria M; Trimboli P
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):822-830. PubMed ID: 32955602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive risk factors for distant metastasis in pediatric differentiated thyroid cancer from Saudi Arabia.
    Parvathareddy SK; Siraj AK; Annaiyappanaidu P; Siraj N; Al-Rasheed M; Al-Haqawi W; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Front Endocrinol (Lausanne); 2023; 14():1228049. PubMed ID: 37867506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer.
    Sezer H; Yazıcı D; Terzioğlu T; Tezelman S; Canbaz HB; Yerlikaya A; Demirkol MO; Kapran Y; Çolakoğlu B; Çilingiroğlu EN; Alagöl F
    Am Surg; 2023 Dec; 89(12):5996-6004. PubMed ID: 37309609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
    Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
    Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of staging and recurrence predictors in patients with differentiated thyroid cancer between the 7th and 8th editions of the American Joint Committee on Cancer staging systems.
    Elbasan O; Gogas Yavuz D
    Minerva Endocrinol (Torino); 2023 Sep; 48(3):261-273. PubMed ID: 36756784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence.
    Karapanou O; Tzanela M; Rondogianni P; Dacou-Voutetakis C; Chiotis D; Vlassopoulou B; Vassiliadi D; Kanaka-Gantenbein C; Tsagarakis S
    Endocrine; 2020 Dec; 70(3):566-574. PubMed ID: 32533509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 17. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of radioiodine avidity and serum thyroglobulin in differentiated thyroid carcinoma with distant metastasis.
    Kim HJ; Lee JI; Kim NK; Min YK; Kim SW; Chung JH
    World J Surg; 2013 Dec; 37(12):2845-52. PubMed ID: 24085223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma.
    Lang BH; Wong KP; Wan KY; Lo CY
    Ann Surg Oncol; 2012 Jan; 19(1):60-7. PubMed ID: 21681379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
    Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
    Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.